These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8889325)

  • 1. Leishmaniasis: Immunological and clinical aspects and vaccines in Venezuela.
    Convit J
    Clin Dermatol; 1996; 14(5):479-87. PubMed ID: 8889325
    [No Abstract]   [Full Text] [Related]  

  • 2. Vaccine for prophylaxis and immunotherapy, Brazil.
    Genaro O; de Toledo VP; da Costa CA; Hermeto MV; Afonso LC; Mayrink W
    Clin Dermatol; 1996; 14(5):503-12. PubMed ID: 8889328
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerin: preliminary report.
    Convit J; Ulrich M; Polegre MA; Avila A; Rodríguez N; Mazzedo MI; Blanco B
    Mem Inst Oswaldo Cruz; 2004 Feb; 99(1):57-62. PubMed ID: 15057348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PKDL and other dermal lesions in HIV co-infected patients with Leishmaniasis: review of clinical presentation in relation to immune responses.
    Zijlstra EE
    PLoS Negl Trop Dis; 2014; 8(11):e3258. PubMed ID: 25412435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy with live BCG plus heat killed Leishmania induces a T helper 1-like response in American cutaneous leishmaniasis patients.
    Cabrera M; Blackwell JM; Castes M; Trujillo D; Convit J; Shaw MA
    Parasite Immunol; 2000 Feb; 22(2):73-9. PubMed ID: 10652119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigen-specific immunodeficiency and its relation to the spectrum of American cutaneous leishmaniasis.
    Convit J; Ulrich M
    Biol Res; 1993; 26(1-2):159-66. PubMed ID: 7545499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical and immunological spectrum of American cutaneous leishmaniasis.
    Convit J; Ulrich M; Fernández CT; Tapia FJ; Cáceres-Dittmar G; Castés M; Rondón AJ
    Trans R Soc Trop Med Hyg; 1993; 87(4):444-8. PubMed ID: 8249076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tegumentary leishmaniasis: what is new in 2000?].
    Piarroux R; Minodier P
    Med Trop (Mars); 2000; 60(1):19-24. PubMed ID: 10989781
    [No Abstract]   [Full Text] [Related]  

  • 9. [Histology of cutaneous leishmaniasis].
    Mokni M; Mebazaa A; Boubaker S
    Ann Dermatol Venereol; 2011; 138(4):354-6. PubMed ID: 21497266
    [No Abstract]   [Full Text] [Related]  

  • 10. Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.
    Salay G; Dorta ML; Santos NM; Mortara RA; Brodskyn C; Oliveira CI; Barbiéri CL; Rodrigues MM
    Clin Vaccine Immunol; 2007 Sep; 14(9):1173-81. PubMed ID: 17626159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy as a treatment of American cutaneous leishmaniasis: preliminary studies in Brazil.
    Mayrink W; Magalhaes PA; Michalick MS; da Costa CA; Lima Ade O; Melo MN; Toledo VP; Nascimento E; Dias M; Genaro O
    Parassitologia; 1992 Dec; 34(1-3):159-65. PubMed ID: 1339971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunopathology of American tegumentary leishmaniasis].
    Castés M; Tapia FJ
    Acta Cient Venez; 1998; 49(1):42-56. PubMed ID: 10205916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leishmaniasis.
    Grevelink SA; Lerner EA
    J Am Acad Dermatol; 1996 Feb; 34(2 Pt 1):257-72. PubMed ID: 8642091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The IgG isotypes of specific antibodies in patients with American cutaneous leishmaniasis; relationship to the cell-mediated immune response.
    Rodríguez V; Centeno M; Ulrich M
    Parasite Immunol; 1996 Jul; 18(7):341-5. PubMed ID: 9229387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adhesion molecules in lesions of American cutaneous leishmaniasis.
    Tapia FJ; Cáceres-Dittmar G; Sánchez MA; Fernández CT; Rondón AJ; Convit J
    Exp Dermatol; 1994 Feb; 3(1):17-22. PubMed ID: 7914808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leishmaniasis vaccine.
    Drugs R D; 1999 Sep; 2(3):208-10. PubMed ID: 10641230
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical and immunopathological aspects of disseminated cutaneous leishmaniasis.
    Carvalho EM; Barral A; Costa JM; Bittencourt A; Marsden P
    Acta Trop; 1994 Apr; 56(4):315-25. PubMed ID: 8023755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of Leishmania-reactive T cells in lesions of American mucocutaneous leishmaniasis (AMCL) patients. Its relevance in the process of healing or aggravation of the disease.
    Conceição-Silva F; Dórea R; Pirmez C; Schubach AO; Cysne L; Coutinho SG
    Mem Inst Oswaldo Cruz; 1988 Nov; 83 Suppl 1():403-6. PubMed ID: 3267032
    [No Abstract]   [Full Text] [Related]  

  • 19. Differential expression of chemokines in patients with localized and diffuse cutaneous American leishmaniasis.
    Ritter U; Moll H; Laskay T; Bröcker E; Velazco O; Becker I; Gillitzer R
    J Infect Dis; 1996 Mar; 173(3):699-709. PubMed ID: 8627035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunopathology of American cutaneous leishmaniasis.
    Pirmez C
    Mem Inst Oswaldo Cruz; 1992; 87 Suppl 5():105-9. PubMed ID: 1342704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.